FindTrial
Sign In

Early Pregnancy Blood Test to Identify Risk of High Blood Pressure (Pre-eclampsia)

SCREENING FOR PRE-ECLAMPSIA USING PREGNANCY-ASSOCIATED PLASMA PROTEIN-A (PAPP-A) AND PLACENTAL GROWTH FACTOR (PLGF) IN EARLY PREGNANCY: A PROSPECTIVE MULTICENTER STUDY - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/098942
Enrollment
1367
Registered
2025-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

A4 Hospitals and Fertility centre Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Singleton pregnancy. Attending first-trimester screening between 8 14 weeks. Able and willing to provide informed consent.

Exclusion criteria

Exclusion criteria: Multiple pregnancies. Known major fetal anomalies. Women unable to understand the consent form language.

Design outcomes

Primary

MeasureTime frame
value of pregnancy-associated plasma protein-A (PAPP-A)Timepoint: 10 months—

Secondary

MeasureTime frame
screening performance of PAPP-A with placental growth factor (PlGF) combined screening performance of maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), and biochemical markers (PAPP-A and PlGF). Timepoint: 10 months—

Countries

India

Contacts

Public ContactShivani gopal

A4 Hospital and Fertility centre Pvt Ltd

drshivanigopal.sg@gmail.com09840119696

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026